Navigation Links
Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
Date:2/9/2011

NEW YORK, Feb 9, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 13th Annual BIO CEO & Investor Conference, being held at the Waldorf=Astoria Hotel in New York City.  Mr. Bentsur's presentation will take place on Monday, February 14th, at 3:00 p.m. Eastern Time.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.KERYX CONTACT:Lauren FischerDirector, Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5962
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... ... 08, 2020 , ... Bode Technology, a leading ... operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical ... provides a turnkey solution that includes a comprehensive collection and virus-management program ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, ... the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor ...
(Date:7/1/2020)... ... 29, 2020 , ... MedShift , a leading medical ... many obstacles created as a result of COVID-19. As a provider at the ... practices and medical manufacturers by expanding access to device offerings, technology services, and ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a leading provider of ... businesses of all types to ensure cleanliness, distancing and occupancy with its patent pending ... Space™ enabled business will provide a health performance index system that scores all aspects ...
Breaking Biology Technology:
(Date:6/19/2020)... ... ... The director of stem cell biotechnology company Asymmetrex , Dr. James L. Sherley, ... easier access to stem cell counting, they will soon make it a routine part ... in the U.S., Asymmetrex is offering free tissue stem cell counting at its ...
(Date:6/19/2020)... TORONTO (PRWEB) , ... June 18, 2020 , ... Join ... Justin Zhao, PhD, Principal Scientist in a live webinar on Wednesday, July ... ZFN have simplified the way we genetically engineer new models. However, while modifying the ...
(Date:6/11/2020)... ... June 08, 2020 , ... Cryo-Cell International’s announcement ... to protect workers in the medical field. The face masks will be distributed ... their lives every day to provide healthcare to pregnant women. The delivery of ...
Breaking Biology News(10 mins):